M. Kauffman
Molecular Biology · New England Journal of Medicine · 2003–2004
A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 9 citations into it
Whom M. Kauffman trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- A. Baldwin (in Molecular Biology)
Papers from M. Kauffman's perspective
Ordered by how strongly the researchers M. Kauffman trusts endorse each paper. Same corpus, a different order for every researcher.
- The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. (Cancer Research)
- Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
- Distinct Roles of the IκB Kinase α and β Subunits in Liberating Nuclear Factor κB (NF-κB) from IκB and in Phosphorylating the p65 Subunit of NF-κB* (Journal of Biological Chemistry)
- Upstream and downstream of mTOR. (Genes & Development)
- mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. (Cell)
- mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways (Nature Medicine)
- AKT/PKB signaling: navigating downstream. (Cell)
- The two NF-κB activation pathways and their role in innate and adaptive immunity
- Akt Stimulates the Transactivation Potential of the RelA/p65 Subunit of NF-κB through Utilization of the IκB Kinase and Activation of the Mitogen-activated Protein Kinase p38* (Journal of Biological Chemistry)
- Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR (Proceedings of the National Academy of Sciences of the United States of America)
Their papers
- A phase 2 study of bortezomib in relapsed, refractory myeloma. (2003) — 2,697 citations
- Development of the Proteasome Inhibitor Velcade™ (Bortezomib) (2004) — 658 citations
- A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma (2004) — 758 citations